AKTS — Aktis Oncology, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2035832 ·
Last close
$16.40
Market Cap
$884.37M
52W High
$34.19
52W Low
$13.96
ADV30
377,889
Next earnings
2026-11-12
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 3,905,000 — -34,747,000 -29,939,000 532,484,000 68,323,000 73,612,000
Jun 2026 3,384,000 — -28,899,000 -24,144,000 557,596,000 82,491,000 72,758,000
Mar 2026 3,227,000 — -22,706,000 -18,325,000 576,801,000 371,630,000 70,693,000
Dec 2025 1,870,000 — -17,375,000 -15,138,000 264,885,000 37,784,000 411,034,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-75,294,000
Investing CF
$-289,389,000
Financing CF
$336,959,000
CapEx
$-9,272,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-199,033,000
Inventory
—
Receivables
—
ST Investments
$434,829,000
EBIT TTM
$-87,183,000
Pretax Income TTM
$-73,140,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$12,386,000
EBITDA
$-100,559,000
Free Cash Flow
$-54,510,376
Enterprise Value
$445,266,176
Total Cash
$492,928,992
Total Debt
$10,835,000
Shares Out
53,925,016
Trailing EPS
$-1.70
Book Value
$8.23
ROE
-26.5%
ROA
-16.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,497,000 -74,684,000 -63,731,000 264,885,000 411,034,000 -146,149,000 -64,127,000
Dec 2024 1,487,000 -52,050,000 -43,980,000 326,181,000 413,984,000 -87,803,000 14,762,000
Dec 2023 0 -34,794,000 -28,641,000 122,355,000 168,661,000 -46,306,000 -30,004,000
Dec 2022 0 -19,764,000 -17,929,000 138,322,000 157,552,000 -19,230,000 -18,125,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$557,596,000
Forward EPS
$-2.21

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $16.40 · call volume: 35 · put volume: 11

Peers — same industry

TickerNameMarket CapLastDaily %
CTY CITY THERAPEUTICS, INC. $887.55M $18.35 —
MTRI InMed Pharmaceuticals Inc. $888.78M $15.24 —
LTGO Latigo Biotherapeutics, Inc. $877.80M $13.24 —
VSTM Verastem, Inc. $864.46M $6.86 —
PHAR Pharming Group N.V. $861.37M $12.17 —

News headlines (Yahoo Finance, 1h cache)

Aktis: Q3 Earnings Snapshot
2026-11-12 13:23 · Yahoo
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
2026-11-12 13:00 · Yahoo
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?
2026-11-11 20:19 · Yahoo
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
2026-10-01 12:00 · Yahoo
Aktis Oncology to Present at Upcoming September Investor Conferences
2026-09-09 12:00 · Yahoo
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
2026-08-19 15:42 · Yahoo
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
2026-08-13 20:01 · Yahoo
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2026-05-04 20:05 · Yahoo
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
2026-05-13 20:30 · Yahoo
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
2026-05-05 14:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.